Is Moderna stock a hold?

An analyst downgrade put one of the year's top-performing stocks under pressure.

| More on:
Doctors and medical specialists look at the results of a drug trial, as the race for a coronavirus vaccine continues

Image source: getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

A recent downgrade from buy to hold from a Wall Street analyst has Moderna (NASDAQ: MRNA) stock under pressure. Needham analyst Alan Carr has removed his $110 price target on the stock, citing valuation concerns.

Moderna's market cap has swelled 885% this year to around $67 billion at recent prices. Despite coming under pressure recently, this is still one of the best performing large-cap healthcare stocks of 2020.

Following a meeting on 17 December with the Food and Drug Administration's independent advisory committee, Moderna's coronavirus vaccine candidate MRNA-1273 will probably become the second vaccine to earn an Emergency Use Authorisation to prevent COVID-19.

Today, the same advisory committee will weigh in on results submitted from Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) regarding their COVID-19 vaccine candidate BNT162b2.

By the end of 2020, Moderna thinks it can deliver enough doses of mRNA-1273 for 10 million Americans, and perhaps produce enough for 500 million people in 2021. That could lead to enormous sales next year, but they probably won't last.

Commercial-stage biotechnology companies generally trade at mid-single-digit multiples of total revenue when that revenue is expected to continue growing at a healthy pace. While Moderna could record a huge windfall in 2021, it isn't likely to last. The next vaccine rolling through Moderna's pipeline probably won't have a chance to launch until 2024.

Forget about holding Moderna. It's time to think about selling your shares. If all goes well with BNT162b2 and at least a few more names on a huge list of coronavirus vaccine candidates, Moderna won't need to manufacture anything at scale by the end of 2022. Without any means to support its enormous valuation, it's hard to see how the stock can rise over the long run. 

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Should you invest $1,000 in Moderna right now?

Before you buy Moderna shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Moderna wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

A man looking at his laptop and thinking.
International Stock News

Is "Magnificent Seven" Laggard Microsoft Ready to Rally?

Let's take a look at the company's most recent report and guidance to see if the stock can continue to…

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
International Stock News

Meta Platforms: AI continues to drive revenue, but is the stock a buy?

Let's take a look.

Read more »

Happy woman working on a laptop.
International Stock News

Do strong earnings results and a dividend hike make Alphabet a growth stock to buy right now?

There was a lot to like from Alphabet's latest print.

Read more »

hands holding up winners cup, asx 200 winning shares
Share Market News

Guess which stock just became the world's most valuable company?

There's a new sheriff (back) in town.

Read more »

a woman holds her hands up in delight as she sits in front of her lap
Share Market News

US jobs report ignites market rally. What could move the needle this week?

All eyes on the Federal Reserve.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
International Stock News

Think Amazon is expensive? These 3 charts might change your mind.

With a market capitalization of $2 trillion, Amazon is now one of the most valuable companies in the world.

Read more »

Business woman with her arms folded stands in front of multiple screens.
International Stock News

How did the Magnificent 7 fare this reporting season?

Let's explore the highlights.

Read more »

A man looking at his laptop and thinking.
International Stock News

Amazon: A good quarter but some concerns

Here's our initial take on Amazon's financial report.

Read more »